Review Article| Volume 36, ISSUE 4, P1180-1187, April 2022

Angiotensin II: A Review of Current Literature

      Up to one-third of all patients admitted to intensive care units carry a diagnosis of shock. The use of angiotensin II is becoming widespread in all forms of shock, including cardiogenic, after the U.S. Food and Drug Administration's (FDA's) initial approval for vasoplegic shock in 2017. Here, the authors review the literature on angiotensin II's mechanism of action, benefits, and future therapeutic opportunities.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Cardiothoracic and Vascular Anesthesia
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Senatore F
        • Jagadeesh G
        • Rose M
        • et al.
        FDA approval of angiotensin II for the treatment of hypotension in adults with distributive shock.
        Am J Cardiovasc Drugs. 2019; 19: 11-20
        • Wakefield BJ
        • Busse LW
        • Khanna AK.
        Angiotensin II in Vasodilatory Shock.
        Crit Care Clin. 2019; 35: 229-245
        • Brand DA
        • Patrick PA
        • Berger JT
        • et al.
        Intensity of Vasopressor Therapy For Septic Shock And The Risk Of In-Hospital Death.
        J Pain Symptom. 2017; 53: 938-943
        • Fyhrquist F
        • Saijonmaa O.
        Renin-angiotensin system revisited.
        J Intern Med. 2008; 264: 224-236
        • Overgaard CB
        • Dzavík V.
        Inotropes and vasopressors: Review of physiology and clinical use in cardiovascular disease.
        Circulation. 2008; 118: 1047-1056
        • van Diepen S
        • Katz JN
        • Albert NM
        • et al.
        Contemporary Management Of Cardiogenic Shock: A scientific statement from the American Heart Association.
        Circulation. 2017; 136: e232-e268
        • Khanna A
        • English SW
        • Wang XS
        • et al.
        Angiotensin II for the treatment of vasodilatory shock.
        N Engl J Med. 2017; 377: 419-430
        • Farina N
        • Bixby A
        • Alaniz C.
        Angiotensin II brings more questions than answers.
        P T. 2018; 43: 685-687
        • Heavner MS
        • McCurdy MT
        • Mazzeffi MA
        • et al.
        Angiotensin II and vasopressin for vasodilatory shock: A critical appraisal of catecholamine-sparing strategies.
        J Intensive Care Med. 2021; 36: 635-645
        • Levin MA
        • Lin H-M
        • Castillo JG
        • et al.
        Early on-cardiopulmonary bypass hypotension and other factors associated with vasoplegic syndrome.
        Circulation. 2009; 120: 1664-1671
        • Tsiouris A
        • Wilson L
        • Haddadin AS
        • et al.
        Risk assessment and outcomes of vasoplegia after cardiac surgery.
        Gen Thorac Cardiovasc Surg. 2017; 65: 557-565
        • Weis F
        • Kilger E
        • Beiras-Fernandez A
        • et al.
        Association between vasopressor dependence and early outcome in patients after cardiac surgery.
        Anaesthesia. 2006; 61: 938-942
        • Hall RI
        • Smith MS
        • Rocker G.
        The systemic inflammatory response to cardiopulmonary bypass: Pathophysiological, therapeutic, and pharmacological considerations.
        Anesth Analg. 1997; 85: 766-782
        • Argenziano M
        • Chen JM
        • Choudhri AF
        • et al.
        Management of vasodilatory shock after cardiac surgery: Identification of predisposing factors and use of a novel pressor agent.
        J Thorac Cardiovasc Surg. 1998; 116: 973-980
        • Papadopoulos G
        • Sintou E
        • Siminelakis S
        • et al.
        Perioperative infusion of low- dose of vasopressin for prevention and management of vasodilatory vasoplegic syndrome in patients undergoing coronary artery bypass grafting-A double-blind randomized study.
        J Cardiothorac Surg. 2010; 5: 17
        • Hajjar LA
        • Vincent JL
        • Barbosa Gomes Galas FR
        • et al.
        Vasopressin versus norepinephrine in patients with vasoplegic shock after cardiac surgery: The VANCS randomized controlled trial.
        Anesthesiology. 2017; 126: 85-93
        • Klijian A
        • Khanna AK
        • Reddy VS
        • et al.
        Treatment with angiotensin II Is associated with rapid blood pressure response and vasopressor sparing in patients with vasoplegia after cardiac surgery: A post-hoc analysis of angiotensin II for the treatment of high-output shock (ATHOS-3) Study.
        J Cardiothorac Vasc Anesth. 2021; 35: 51-58
        • Lehman L-W
        • Saeed M
        • Moody G
        • et al.
        Hypotension as a risk factor for acute kidney injury in ICU patients.
        Comput Cardiol. 2010; 37: 1095-1098
        • Dünser MW
        • Ruokonen E
        • Pettilä V
        • et al.
        Association of arterial blood pressure and vasopressor load with septic shock mortality: A post hoc analysis of a multicenter trial.
        Crit Care. 2009; 13: R181
        • Badin J
        • Boulain T
        • Ehrmann S
        • et al.
        Relation between mean arterial pressure and renal function in the early phase of shock: A prospective, explorative cohort study.
        Crit Care. 2011; 15: R135
        • Bussard RL
        • Busse LW.
        Angiotensin II: A new therapeutic option for vasodilatory shock.
        Ther Clin Risk Manag. 2018; 14: 1287-1298
        • Tumlin JA
        • Murugan R
        • Deane AM
        • et al.
        Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II.
        Crit Care Med. 2018; 46: 949-957
        • Busse LW
        • Wang XS
        • Chalikonda DM
        • et al.
        Clinical experience with IV angiotensin II administration: A systematic review of safety.
        Crit Care Med. 2017; 45: 1285-1294
        • Smith SE
        • Newsome AS
        • Guo Y
        • et al.
        A multicenter observational cohort study of angiotensin II in shock.
        J Intensive Care Med. 2022; 37: 75-82
        • Bassi E
        • Park M
        • Azevedo LCP.
        Therapeutic strategies for high-dose vasopressor-dependent shock.
        Crit Care Res Pract. 2013; 2013654708
        • Nandhabalan P
        • Ioannou N
        • Meadows C
        • et al.
        Refractory septic shock: Our pragmatic approach.
        Crit Care. 2018; 22: 215
        • Bellomo R
        • Wunderink RG
        • Szerlip H
        • et al.
        Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock.
        Crit Care. 2020; 24: 43
        • Papazisi O
        • Palmen M
        • Danser AHJ.
        The Use of Angiotensin II for the Treatment of Post-cardiopulmonary Bypass Vasoplegia.
        Cardiovasc Drugs Ther. 2020;
        • Cutler NS
        • Rasmussen BM
        • Bredeck JF
        • et al.
        Angiotensin II for Critically Ill Patients With Shock After Heart Transplant.
        J Cardiothorac Vasc Anesth. 2020; (S1053-0770(20)30792-8)
        • Trethowan B
        • Michaud CJ
        • Fifer S.
        Use of angiotensin II in Severe vasoplegia after left pneumonectomy requiring cardiopulmonary bypass: A renin response analysis.
        Crit Care Med. 2020; 48: e912-e915
        • Cutler NS
        • Khanna AK.
        Catecholamine-sparing effect of angiotensin II in an anephric patient with mixed shock after cardiac revascularization surgery: A case report.
        A A Pract. 2020; 14: e01266
        • Carpenter JE
        • Murray BP
        • Saghafi R
        • et al.
        Successful treatment of antihypertensive overdose using intravenous angiotensin II.
        J Emerg Med. 2019; 57: 339-344
      1. U.S. National Library of Medicine - Angiotensin II Clinical Trials. Available at: Accessed March 30, 2021.

        • Bellomo R
        • Forni LG
        • Busse LW
        • et al.
        Renin and survival in patients given angiotensin II for catecholamine-resistant vasodilatory shock. A clinical trial.
        Am J Respir Crit Care Med. 2020; 202: 1253-1261
        • Casey JD
        • Semler MW.
        Renin, angiotensin II, and the journey to evidence-based individual treatment effects.
        Am J Respir Crit Care Med. 2020; 202: 1209-1210
        • Bakker J
        • Grover R
        • McLuckie A
        • et al.
        Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002).
        Crit Care Med. 2004; 32: 1-12
        • López A
        • Lorente JA
        • Steingrub J
        • et al.
        Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock.
        Crit Care Med. 2004; 32: 21-30
        • Wieruszewski PM
        • Wittwer ED
        • Kashani KB
        • et al.
        Angiotensin II infusion for shock: A multicenter study of postmarketing use.
        Chest. 2021; 159: 596-605
        • Alam A
        • Burkhoff D
        • Enter DH
        • et al.
        Underutilized fuel: Angiotensin II for vasoplegia in the heart failure patient population.
        J Cardiothorac Vasc Anesth. 2021; (S1053-0770(21)00330-X)